We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 354

Universities abroad experiment with no-fee licensing to drive biotech partnerships

  • Shook Hardy & Bacon LLP
  • -
  • Australia, Canada, European Union, United Kingdom, USA
  • -
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Support growing for request that FDA freeze biosimilar applications

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • February 21 2013

The Washington Legal Foundation (WLF), a public interest law and policy center, has filed comments with the U.S. Food and Drug Administration (FDA

Biotech Life Sciences trade mission to Australia announced

  • Shook Hardy & Bacon LLP
  • -
  • Australia, USA
  • -
  • June 21 2012

The U.S. Department of Commerce, International Trade Administration and U.S. and Foreign Commercial Service have announced an October 29-November 2, 2012, Biotech Life Sciences trade mission to Australia

FDA brings successful enforcement actions against dietary supplement makers

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 1 2012

The U.S. Food and Drug Administration (FDA) has obtained a permanent injunction against Truman Berst who sells, as Alternative Health & Herbs Remedies, herbs and dietary supplements with disease-treatment claims

Federal Circuit reverses Patent Appeals Board on obviousness ruling and commercial success evidence

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 13 2011

The Federal Circuit Court of Appeals has determined that the Board of Patent Appeals and Interferences incorrectly rejected on obviousness grounds a patent claim involving physical and air shields to prevent the clogging of a nozzle to a Wurster coater, which sprays coating material onto pharmaceutical ingredients

FDA warns radiopharmaceutical maker over manufacturing practices

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 17 2011

The Food and Drug Administration (FDA) has issued a warning letter to International Isotopes, Inc., indicating that an inspection revealed “significant violations of Current Good Manufacturing Practices (CGMP) for finished pharmaceuticals.”

Biotech secures $5.3 million for immunosuppressant drug research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

San Francisco-based startup, Nurix, Inc., which reportedly develops T-cellspecific immunosuppressants used to treat autoimmune diseases such as

FTC report on Authorized Generic Drugs generates comment and concern

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 22 2011

The Federal Trade Commission has released a report titled “Authorized Generic Drugs: Short-Term Effects and Long-Term Impact,” in which the agency concludes that “pay-for-delay” agreements between name-brand drug manufacturers and generic drug makers is “a practice that causes substantial consumer harm” by keeping drug prices high

Parties to gene patent dispute change course by seeking U.S. Supreme Court review

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 20 2011

After filing petitions for rehearing before the Federal Circuit Court of Appeals panel that split over whether genetic discoveries can be patented, the parties have apparently changed course and indicated their intent to petition the U.S. Supreme Court for review

Joint public meeting to focus on bridging nanotechnology research

  • Shook Hardy & Bacon LLP
  • -
  • European Union, USA
  • -
  • February 24 2011

The National Nanotechnology Coordination Office has announced that it will spearhead a public meeting to focus on "environmental health and safety questions for nanomaterials and nanotechnology-enabled products" and to "encourage joint US-EU programs of work that would leverage resources."